Objective To report an evidence-based treatment of Mycophenolate Mofetil for idiopathic membranous nephropathy (IMN) with nephrotic syndrome (NS). Methods We searched The Cochrane Library (Issue 3, 2005), MEDLINE (1978 to 2006) and CNKI (1978 to 2006), and critically appraised the available evidence. Results The available Level C (low quality) evidence showed that Mycophenolate Mofetil was effective for the remission of proteinuria, and effective in patients who were resistant to steroid or cytotoxic agents. However, there was no evidence on its long-term effect on renal survival. Given the current evidence, together with our clinical experience and the patient’s preference, Mycophenolate Mofetil and glucocorticoid were administered to the patient. After 3 months of treatment, proteinuria was relieved. The patient is still can followed up. Conclusions We only find Level C evidence to support the short-term efficacy of Mycophenolate Mofetil on the remission of proteinuria. Further studies on its long-term effects on renal survival, and a health economics evaluation are needed.
【摘要】 目的 发现提示早期Ⅴ型狼疮性肾炎(lupus nephritis,LN)的指标。 方法 2004年 1月-2009年11月24例经肾活检诊断为Ⅴ型LN患者,与同期50例膜性肾病伴抗核抗体(antinuclear antibody,ANA)阳性患者、50例膜性肾病ANA阴性患者,以及13例膜性肾病ANA阳性且肾组织荧光为“满堂亮”患者的一般资料、肾病表现、肾脏病理以及实验室指标进行比较。 结果 Ⅴ型LN与膜性肾病ANA阴性的患者相比,两组的性别、起病年龄、血红蛋白、补体水平、内皮和系膜增殖的比例等有明显差异。膜性肾病ANA阳性患者的临床和病理表现更接近于ANA阴性的膜性肾病,但其性别比仍以女性居多。而膜性肾病ANA阳性伴“满堂亮”的患者在性别、肾病表现、血红蛋白、补体水平等方面与Ⅴ型LN更为接近。 结论 膜性肾病ANA阳性患者具有异质性,其中肾脏病理表现为“满堂亮”的患者可能系早期Ⅴ型LN。【Abstract】 Objective To find out the clinical and pathological characteristics of early pure class Ⅴ lupus nephritis (LN). Methods A total of 24 patients with pure class Ⅴ LN diagnosed between January 2004 and November 2009 were included, and were compared with 50 antinuclear antibody (ANA)-positive patients with membranous nephropathy (MN) and 50 ANA-negative patients with MN. The clinical and pathological characteristics, laboratory test results were compared between the two groups. Then, 13 patients with "full house" fluorescence in renal biopsy specimens were chosen from the group of ANA-positive membranous nephropathy, whose clinical characteristics and laboratory test were compared with class Ⅴ LN patients. Results There were significant differences in sex ratio, age, positive rate of hepatitis B surface antigen (HBsAg), levels of hemoglobin, white blood cell, platelet,complement, endothelial and mesangial proliferation between class Ⅴ LN and ANA-negative MN group. However, the sex ratio, levels of white blood cell, platelet were similar between class Ⅴ LN and ANA-positive MN group. The renal biopsy specimens in patients with ANA-positive MN with "full house" fluorescence were similar with those in the patients with class Ⅴ LN in sex ratio, renal injury, hemoglobin and complement and the positive rate of hepatitis B surface antigen. Conclusion The demographic information and clinical manifestations in patients with class Ⅴ LN were similar to those in patients with ANA positive MN, especially in the patients wiht ANA-positive MN with "full house" fluorescence in renal biopsy specimens.
Objective We intended to get a good understanding of the current role of alkylating agents in the treatment of idiopathic membranous nephropathy (IMN) with nephrotic syndrome (NS). Methods We searched the Cochrane Library ( Issue 3, 2005), MEDLINE (1978 Jun., 2005) and CBM disc(1978-2005) to get the current best evidence of alkylating agents for treating IMN with NS and further critically appraised the available evidence. Results Alkylating agents showed a significant beneficial effect on complete remission of proteinuria. The treatment of glucocorticoid with cyclophosphamide (MP+CTX) was one of the best managements among the various regimens suggested for IMN, but it was not clear about its long-term effect on renal survival rate. Given the current best evidence together with our clinical experience and the attitudes of the patient and family members, the treatment of (MP+CTX) was administered. There was a significant remission of proteinuria after 6 months follow-up. Conclusions The treatment of (MP+CTX) can significantly improve the remission of proteinuria, however further observations on the long-term effect of alkylating agents on renal survival rate are required.
ObjectiveTo systematically review the value of autoantibodies to serum M-type phospholipase A2 receptor (PLA2R) in predicting spontaneous and therapeutic remission rates of idiopathic membranous nephropathy (IMN).MethodsPubMed, Embase, Clinical Trails, China National Knowledge Infrastructure, China Biology Medicine, Wanfang, and CQVIP databases were searched for studies on remission of IMN associated with PLA2R antibody published from inception to December 2020. Binary variables were extracted according to PLA2R antibody positive and negative groups. Newcastle-Ottawa Scale was used to evaluate the literature quality. Meta analyses were performed in RevMan 5.3 software, and relative risk (RR) and its 95% confidence interval (CI) were calculated. Publication bias was analyzed by Stata 15.0 software.ResultsA total of 15 articles were included in the meta-analysis, all of which were cohort studies (erther retrospective or prospective). A total of 1 452 patients with IMN were enrolled in the study. Among them, the spontaneous remission rate of IMN patients without immunosuppressive therapy was observed in 6 articles, and the therapeutic remission rate of IMN patients receiving immunosuppressive therapy was observed in 13 articles (both spontaneous remission rate and therapeutic remission rate were observed in 4 articles). Meta-analysis results showed that the spontaneous remission rate in the PLA2R antibody positive group was significantly lower than that in the PLA2R antibody negative group [RR=0.73, 95%CI (0.55, 0.97), P=0.03]. For IMN patients receiving immunosuppressive therapy, the remission rate in the PLA2R antibody positive group was significantly lower than that in the PLA2R antibody negative group at diagnosis [RR=0.81, 95%CI (0.72, 0.92), P=0.000 9].ConclusionsThe spontaneous remission rate of IMN with PLA2R antibody positive at diagnosis and the remission rate under the immunosuppressive therapy are significantly lower than those with PLA2R antibody negative. For IMN patients with negative PLA2R antibody, non-immunosuppressive therapy may be preferred to reduce the risk of adverse reactions due to its relatively high spontaneous remission rate. For IMN patients with PLA2R antibody positive, a more aggressive, longer-term immunosuppressive therapy may be required, given its lower spontaneous and therapeutic remission rates.